Cyclizine
 |
|
 |
|
| Clinical data | |
|---|---|
| Trade names | Marezine, Valoid, Nausicalm |
| AHFS/Drugs.com | Consumer Drug Information |
| Pregnancy category |
|
| Routes of administration |
Oral, IM, IV |
| ATC code | R06AE03 (WHO) |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Metabolism | N-demethylated to inactive norcyclizine[1] |
| Biological half-life | 20 hours |
| Identifiers | |
|
Systematic (IUPAC) name: 1-benzhydryl-4-methyl-piperazine
|
|
| CAS Number | 82-92-8  |
| PubChem (CID) | 6726 |
| IUPHAR/BPS | 7151 |
| DrugBank | DB01176 |
| ChemSpider | 6470 |
| UNII | QRW9FCR9P2 |
| KEGG | D03621 |
| ChEBI | CHEBI:3994 |
| ChEMBL | CHEMBL648 |
| Chemical and physical data | |
| Formula | C18H22N2 |
| Molar mass | 266.381 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
| (verify) | |
Cyclizine is an antihistamine drug used to treat nausea, vomiting and dizziness associated with motion sickness, vertigo and post-operatively following administration of general anaesthesia and opioids.
It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system.[2]
Contents
Medical uses[edit]
Nausea, vomiting and dizziness associated with motion sickness, vertigo and post-operatively following administration of general anaesthesia and opioids. It is sometimes given in hyperemesis gravidarum, although the manufacturer advises that it be avoided in pregnancy. Off-licence use often occurs with specialists in hospitals to treat inpatients who have become severely dehydrated in pregnancy. An off-label use is as an opioid/opiate potentiator.[3]
The drug Diconal is a combination of cyclizine with the opioid dipipanone.[4] Dipipanone is a schedule I controlled substance in the US, due to its high abuse potential.
Contraindications[edit]
Its antimuscarinic action warrants caution in patients with prostatic hypertrophy, urinary retention, or angle-closure glaucoma. Liver disease exacerbates its sedative effects.[3]
Adverse effects[edit]
Common (over 10%) — Drowsiness, xerostomia (dry mouth).
Uncommon (1% to 10%) — Headache, psychomotor impairment, dermatitis, and antimuscarinic effects such as diplopia (double vision), tachycardia, constipation, urinary retention and gastro-intestinal disturbances.
Rare (less than 1%) — Hypersensitivity reactions (bronchospasm, angioedema, anaphylaxis, rashes and photosensitivity reactions), extrapyramidal effects, dizziness, confusion, depression, sleep disturbances, tremor, liver dysfunction, and hallucinations.
Pharmacology[edit]
Cyclizine is a piperazine derivative with histamine H1-receptor antagonist (antihistamine) activity. The precise mechanism of action in inhibiting the symptoms of motion sickness is not well understood. It may have effects directly on the vestibular apparatus and on the chemoreceptor trigger zone. Cyclizine exerts a central anticholinergic (antimuscarinic) action.[3]
History[edit]
Cyclizine was developed in the American division of pharmacy company Burroughs Wellcome (today GlaxoSmithKline) during a research involving many drugs of the antihistamine group. Cyclizine was quickly clinically found as a potent and long-acting antiemetic. Company named the substance – or more precisely cyclizine's hydrochloride form which it usually appears in – "marezine hydrochloride" and started to sell it in the United States under trade name Marezine. Selling was begun in France under trade name Marzine in 1965.[5][6]
The substance received more credit when NASA chose it as a space antiemetic for the first occupied moon flight. Cyclizine was introduced to many countries as a common antiemetic. It is an over-the-counter drug in many countries because it has been well tolerated, although it has not been very much studied.[5][7]
Society and culture[edit]
Some people using methadone recreationally combine cyclizine with their methadone dose, a combination that is known to produce strong psychoactive effects.[8] It has also been used recreationally for its anticholinergic effects to induce hallucinations.[9]
It has also been used illegally in greyhound racing to sabotage a dog's performance.[10]
Names[edit]
As cyclizine hydrochloride tablets and cyclizine lactate solution for intramuscular or intravenous injection (brand names: Valoid[3] in UK and Marezine, Marzine and Emoquil in US). Cyclizine is marketed as Bonine for Kids in the US.[11]
Cyclizine derivatives[edit]
| Structural comparison of cyclizine and related H1 antagonists[12] |
||
|---|---|---|
 |
||
| Compound | R1 | R2 |
| Cyclizine | H | CH3 |
| Chlorcyclizine | Cl | CH3 |
| Meclizine | Cl |  |
| Buclizine | Cl |  |
| Oxatomide | H |  |
| Hydroxyzine | Cl |  |
| Cetirizine | Cl |  |
See also[edit]
References[edit]
- ^ "DrugBank: Cyclizine. Pharmacology: metabolism". DrugBank Database. Retrieved 5 January 2016.
- ^ "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.
- ^ a b c d "Valoid Tablets by Amdipharm". Electronic Medicines Compendium. Datapharm.
- ^ "Diconal Tablets by Amdipharm". Electronic Medicines Compendium. Datapharm.
- ^ a b Sneader, Walter (2005). Drug discovery: a history. John Wiley & Sons. p. 404. ISBN 0-471-89979-8.
- ^ Sittig, Marshall (1988). Pharmaceutical manufacturing encyclopedia. William Andrew. p. 406. ISBN 0-8155-1144-2.
- ^ http://www.drugs.smd.qmul.ac.uk/drugs/html5/Anti-emetics/AN-FEF54A37-6289-402B-E208-9284E183608A.html
- ^ Ruben, S. M.; McLean, P. C.; Melville, J. (1989). "Cyclizine abuse among a group of opiate dependents receiving methadone". British Journal of Addiction. 84 (8): 929–934. doi:10.1111/j.1360-0443.1989.tb00766.x. PMID 2775912.
- ^ Bassett, K.; Schunk, J. E.; Crouch, B. I. (1996). "Cyclizine abuse by teenagers in Utah". The American Journal of Emergency Medicine. 14 (5): 472–474. doi:10.1016/S0735-6757(96)90156-4. PMID 8765114.
- ^ Conor Ryan for The Independent. June 20, 2013 IGB left with €250k bill after dog doping case
- ^ "Bonine for Kids". Insight Pharmaceuticals.
- ^ Lemke, Thomas L.; Williams, David A.; Roche, Victoria F.; Zito, S. William, eds. (2013). Foye's Principles of Medicinal Chemistry (7th ed.). Philadelphia: Wolters Kluwer Health / Lippincott Williams & Wilkins. p. 1056. ISBN 1-60913-345-5.
